Oxygen Biotherapeutics, Inc. Expands Board of Directors
Adds Lt. Gen. Ronald R. Blanck (Ret.)
DURHAM, N.C., Dec. 14 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) today announced the expansion of the company's board of directors with the addition of Lt. Gen. Ronald R. Blanck, DO, U.S. Army (Ret.). Dr. Blanck is chairman of Martin, Blanck & Associates, a federal health services consulting firm based in Falls Church, Virginia. With his addition, the company board now has nine members.
Dr. Blanck began his military career in 1968 as a medical officer and battalion surgeon in Vietnam. He retired 32 years later as a Lieutenant General and Surgeon General of the U.S. Army and commander of the U.S. Army Medical Command with more than 46,000 military personnel and 26,000 civilian employees throughout the world. During his distinguished military career, Dr. Blanck also served as commander of Walter Reed Medical Center and the North Atlantic Region Medical Command.
After his military service and prior to joining Martin, Blanck & Associates, Dr. Blanck served as the president of the University of North Texas Health Science Center at Fort Worth. As president, Dr. Blanck headed a growing academic health center that includes the Texas College of Osteopathic Medicine, Graduate School of Biomedical Sciences, School of Public Health and School of Health Professions.
"I am very honored that an individual with Ron Blanck's combination of military and medical credentials is coming onto our board of directors, especially as we look toward expanding our efforts in Defense Medicine(TM). As you know, we believe Oxycyte(TM) has the potential to help reduce the long-term brain damage to our forces who are blast injury casualties in Iraq and Afghanistan. His medical expertise and his military contacts should be helpful in our efforts in this area," said Chris Stern, company chairman and CEO.
"Also, this expansion of the board is part of our goal to change the board's structure so that it builds out its majority of independent outside directors, something I believe is important in view to a move to a major exchange listing," said Stern.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has developed a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(TM)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications which are being marketed under the Dermacyte name. More information is available at www.oxybiomed.com.
SOURCE Oxygen Biotherapeutics, Inc.
Abe Wischnia, Abe Wischnia & Associates, +1-619-795-2345